

EGC

Total


Laparoskopi

CLASS02 (RCT)

2017-2018

Non-inferiority


Early operative morbidity and mortality rate



Morbidity type/mortality	Surgery				Between-group difference, RD, % (95% CI) ^a
	No.	Rate, % (95% CI)	No.	Rate, % (95% CI)	
All complications	20	19.1 (11.5 to 26.6)	22	20.2 (12.7 to 27.7)	-1.1 (-11.8 to 9.6)
Intraoperative complications	3	2.9 (0 to 6.0)	4	3.7 (0.1 to 7.2)	-0.8 (-6.5 to 4.9)
Massive hemorrhage	3	2.9 (0 to 6.0)	3	2.8 (0 to 5.8)	0.1 (-5.3 to 5.6)
Spleen injury	0	0	1	0.9 (0 to 2.7)	-0.9 (-5.0 to 2.7)
Postoperative complications	19	18.1 (10.7 to 25.5)	19	17.4 (10.3 to 24.6)	0.7 (-9.6 to 11.0)
Anastomotic					
Leakage	1	1.0 (0 to 2.8)	1	0.9 (0 to 2.7)	0 (-4.1 to 4.4)
Bleeding	0	0	1	0.9 (0 to 2.7)	-0.9 (-5.0 to 2.7)
Stenosis	2	1.9 (0 to 4.5)	2	1.8 (0 to 4.4)	0.1 (-4.7 to 5.0)
Wound problem	3	2.9 (0 to 6.0)	1	0.9 (0 to 2.7)	1.9 (-2.6 to 7.2)
Intra-abdominal					
Bleeding	3	2.9 (0 to 6.0)	0	0	2.9 (-1.0 to 8.1)
Abscess	5	4.8 (0.7 to 8.8)	5	4.6 (0.7 to 8.5)	0.2 (-6.1 to 6.6)
Ileus	2	1.9 (0 to 4.5)	1	0.9 (0 to 2.7)	1.0 (-3.3 to 5.8)
Lymphatic leakage	1	1.0 (0 to 2.8)	1	0.9 (0 to 2.7)	0 (-4.1 to 4.4)
Pancreatic fistula	0	0	2	1.8 (0 to 4.4)	-1.8 (-6.4 to 1.9)
Pancreatitis	1	1.0 (0 to 2.8)	0	0	1.0 (-2.5 to 5.2)
Pulmonary	5	4.8 (0.7 to 8.8)	10	9.2 (3.8 to 14.6)	-4.4 (-11.8 to 2.8)
Cerebrovascular	0	0	1	0.9 (0 to 2.7)	-0.9 (-5.0 to 2.7)
Pleural effusion	7	6.7 (1.9 to 11.4)	5	4.6 (0.7 to 8.5)	2.1 (-4.6 to 9.1)
Deep vein thrombosis	1	1.0 (0 to 2.8)	0	0	1.0 (-2.5 to 5.2)
Renal	0	0	1	0.9 (0 to 2.7)	-0.9 (-5.0 to 2.7)
Others	1	1.0 (0 to 2.8)	0	0	1.0 (-2.5 to 5.2)
Mortality	1	1.0 (0 to 2.8)	0	0	1.0 (-2.5 to 5.2)

FINDINGS

Rates of combined morbidity and mortality were not significantly different among patients receiving laparoscopic vs open total gastrectomy



Rate difference, laparoscopic vs open total gastrectomy: -1.1% (95% CI, -11.8% to 9.6%)

The results of the CLASS02 trial showed that the **safety** of LTG with lymphadenectomy by experienced surgeons for clinical stage I.

AGC

Total


Laparoskopi

KLASS06

Multicenter, Prospective, Phase III trial

Primary endpoint: 3 year relapse free survival

Estimated sample size - 772 patients



~772 hasta
Tarih: 2018-2027